Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TriSalus Life Sciences, Inc.

Get SEC filing alerts via email and in your feed for TriSalus Life Sciences, Inc.

TLSI TLSIW

TriSalus Life Sciences, Inc.

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences specializes in innovative medical technologies for delivering therapeutics to solid tumors, focusing on liver and pancreatic cancers. Its core platform, Pressure-Enabled Drug Delivery (PEDD), enhances targeted treatment via FDA-cleared devices like TriNav, improving drug penetration and reducing off-target effects. The company also develops immunotherapeutic agents, such as nelitolimod, to modulate tumor microenvironments and boost immunotherapy efficacy. Its approach aims to address significant treatment barriers and improve patient outcomes in oncology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TriSalus Life Sciences, Inc.

1
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports Q1 2026 Revenue of $8.9 Million, Expands Product Offerings

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports 53.4% Revenue Increase but Continues Operating Loss in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports 57.4% Revenue Growth but Faces $41.3 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports 52.3% Revenue Growth but Incurred $9M Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports 42% Revenue Growth to $9.2 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports $33.2 Million Net Loss and 59% Revenue Growth in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TriSalus Life Sciences, Inc. TriSalus Life Sciences Reports Revenue Growth, Improved Operating Loss, and Strategic Developments in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments